Results 121 to 130 of about 81,306 (284)

Blockage of Nrf2/AKR1C axis enhanced therapeutic efficacy of oxaliplatin in oxaliplatin resistant gastric cancer cells

, 2013
[[abstract]]Background: Oxaliplatin is one of the major cytotoxic chemotherapeutic agents for the treatment of advanced gastrointestinal tract cancer, including pancreatic cancer, but the underlying mechanisms of acquired oxaliplatin resistance remain ...
Kuo, C;Chu, C;Huang, C;Chang, J;Pan, W;Chen, L
core   +1 more source

Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy‐Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post‐Treatment

International Journal of Cancer, EarlyView.
ABSTRACT Chemotherapy‐induced peripheral neuropathy (CIPN) is a potentially long‐term consequence of oxaliplatin‐based chemotherapy for colorectal cancer (CRC). Oxaliplatin dosing is based on body surface area (BSA), but lean body mass (LBM) may influence susceptibility to long‐term CIPN.
Nadira R. Querido, Martijn J. L. Bours, Liselot Valkenburg‐van Iersel, Antoinetta J. M. Beijers, Stephanie O. Breukink, Maryska L. G. Janssen‐Heijnen, Eric T. P. Keulen, Joop L. M. Konsten, Judith de Vos‐Geelen, Matty P. Weijenberg, Colinda C. J. M. Simons   +10 more
wiley   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Oxaliplatin-Loaded Mil-100(Fe) for Chemotherapy–Ferroptosis Combined Therapy for Gastric Cancer

Oxaliplatin (Oxa) is a commonly used chemotherapy drug in the treatment of gastric cancer, but its toxic side effects and drug resistance after long-term use have seriously limited its efficacy.
Xuewei Zheng (9617558), Xiaoyu Zhang (62901), Boyao Sun (11486203), Huaiyu Zhang (439766), Yang Jiang (46459)   +4 more
core   +1 more source

Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Proton pump inhibitors (PPIs) are commonly prescribed in patients with cancer. Prior studies suggest concomitant PPI use may reduce the efficacy of oral capecitabine through impaired absorption, with no interaction expected with intravenous 5‐fluorouracil (5‐FU). Using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD),
Matthew Loft, Vinoja Ganeshanathan, Rachel Wong, Shehara Mendis, Matthew Croxford, Ian T. Jones, Grace Gard, Sue‐Anne McLachlan, Jeanne Tie, Lucy Gately, Peter Gibbs   +10 more
wiley   +1 more source

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study

, 2015
Norbert Marschner,1 Dirk Arnold,2 Erik Engel,3 Ulrich Hutzschenreuter,4 Jacqueline Rauh,5 Werner Freier,6 Holger Hartmann,7 Melanie Frank,8 Martina Jänicke7 On behalf of the TKK Registry Group 1Praxis für Interdisziplinäre Onkologie und ...
Marschner N, Engel E, Jänicke M, Rauh J, Arnold D, Frank M, Freier W, Hutzschenreuter U, Hartmann H   +8 more
core  

Fertility counseling and preservation considerations in patients with gynecologic and non‐gynecologic BRCA and Lynch‐associated malignancies

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Lynch syndrome and BRCA‐mutation associated malignancies are fortunately rare. Affected patients have an increased risk of cancer diagnosis at a young age, often significantly overlapping with their reproductive years. In helping these patients, oncologists must navigate the following areas of care: cancer prevention, impact of cancer ...
Anna Weimer, Nadeem Abu‐Rustum, David Mutch, Mauricio Cuello, Angélica Fletcher, Hextan Y. S. Ngan, Nozomu Yanaihara, Rene Pareja, Christina Fotopoulou, Kenneth Ruzindana, Ka Yu Tse, Yana Zou, Neerja Bhatla, Ting‐Chang Chang, Munanchiso Ndukwe Iheme Jr, Jalid Sehouli, Nicole Conchin, Eva Chalas, Sarikapan Wilailak, Barbara Schmalfeldt, Alexander B. Olawaiye   +20 more
wiley   +1 more source

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

Oncogenesis
Oxaliplatin is effective against colorectal cancer (CRC), but resistance hampers treatment. We found upregulated Dickkopf-1 (DKK1, a secreted protein) in oxaliplatin-resistant (OR) CRC cell lines and DKK1 levels increased by more than 2-fold in ...
Chi-Che Hsieh, Ting-Wei Li, Chun-Chun Li, Shang-Hung Chen, You-Lin Wei, Nai-Jung Chiang, Che-Hung Shen   +6 more
doaj   +1 more source

A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer using Oxaliplatin and Coxsackievirus A11

, 2018
Background: Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death.
Wang, BEIBEI, 王, 蓓蓓, オウ, バイバイ   +2 more
core  

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source